International Journal of Hematology and Oncology 2020, Vol 30, Num 2 Page(s): 054-062
Prognostic Factors in Squamous Cell Carcinoma of the Vulva: a Retrospective Multicenter Study

Oguzhan KURU1, Utku AKGOR2, Ilker CAKIR1, Ozgur TOSUN3, Ilkbal Temel YUKSEL4, Volkan ULKER4, Mutlu MEYDANLI5, Muzaffer SANCI1, Mehmet GOKCU1, Samet TOPUZ3, Ferah YILDIZ6, Mehmet SAKINCI7, Mehmet Coskun SALMAN2, Nejat OZGUL2, Kunter YUCE2, Ali AYHAN8

1Izmir Tepecik Training And Research Hospital, Department of Gynecologic Oncology, Izmir, TURKEY
2Hacettepe University, Faculty of Medicine, Department of Gynecologic Oncology, Ankara, TURKEY
3Istanbul University, Faculty of Medicine, Department of Gynecologic Oncology, Istanbul, TURKEY
4Kanuni Sultan Suleyman Training and Research Hospital, Department of Gynecologic Oncology, Istanbul, TURKEY
5Zekai Tahir Burak Women’s Health Training and Research Hospital, Department of Gynecologic Oncology, Ankara, TURKEY
6Hacettepe University, Faculty of Medicine, Department of Radiation Oncology, Ankara, TURKEY
7Akdeniz University Faculty of Medicine, Department of Obstetrics and Gynecology, Antalya, TURKEY
8Baskent University, Faculty of Medicine, Department of Gynecologic Oncology, Ankara, TURKEY

Keywords: Metformin, Prognosis, Recurrence, Survival, Vulvar cancer
The study aim to determine the clinicopathological factors for disease-free survival (DFS) and overall survival (OS) in women with vulvar cancer and to analyze the the possible effect of metformin on survival of the patients. From 2011 to 2017, medical records of 142 patients who underwent primary radical surgery for VC at 6 referral centers in Turkey were collected, retrospectively. The median age of the cohort was 67.0 years. 124 patients underwent radical surgery and inguinofemoral lymphadenectomy. The overall recurrence rate was 33.8% within a median follow-up time of 22 months. Five-year DFS and OS rates were 55.8% and 62.6%, respectively. Multivariate analysis showed surgical margin (HR:6.4, p= 0.017 for DFS; HR:13.6, p=0.009 for OS) and lymph node metastasis (HR: 4.1, p= 0.014 for DFS; HR: 6.3, p= 0.020 for OS) were the independent prognostic factors. There was no statistically difference in DFS and OS for patients who had used metformin.